Literature DB >> 11901059

Immunometric assay interference: incidence and prevention.

Johan Bjerner1, Kjell Nustad, Lars F Norum, Kari Hauge Olsen, Ole P Børmer.   

Abstract

BACKGROUND: The primary aim of the study was to reduce interference in an in-house two-site, two-step immunometric assay.
METHODS: In the running laboratory routine, 11 261 samples were tested with a carcinoembryonic antigen (CEA) assay with bovine immunoglobulin but no murine immunoglobulins in the buffer, in parallel to our routine CEA assay, using 15 mg/L heat-treated nonspecific murine immunoglobulin (MAK33) in the buffer and with the Fc fragments removed from the capture antibody.
RESULTS: The frequency of interference was estimated to be 4.0% (95% confidence interval, 3.3-4.7%). The addition of 15 mg/L native MAK33 had little effect (frequency, 3.9%; 95% confidence interval, 3.2-4.6%), whereas adding 15 mg/L heat-treated MAK33 reduced interference to 0.86% (0.61-1.12%), and adding 50 mg/L reduced it further to 0.06% (0-0.13%). Removing the Fc fragments by itself reduced interference to 0.10% (0.02-0.19%). There were no statistically significant differences for age (P <0.23) or gender (P <0.40) between patients with interference (n = 210) and a randomly selected interference-negative control group (n = 186). Interference was not constant in patients: 15 of 25 individuals positive for interference and with four or more samples screened for interference had an interference-negative sample either before or after the peak of interference.
CONCLUSIONS: In a two-site, two-step immunometric assay using mouse monoclonal antibodies, use of heat-treated nonspecific murine immunoglobulin in the buffer or removal of the Fc fragment from the capture antibody could improve performance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11901059

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  13 in total

1.  Multiple admissions to the coronary care unit due to falsely elevated cardiac troponin.

Authors:  Mohamed Ayan; Zaid Gheith; Aneesha Ananthula; Mohsin Salih; Srikanth Vallurupalli; Jawahar L Mehta
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-03-15

2.  TSH Comparison Between Chemiluminescence (Architect) and Electrochemiluminescence (Cobas) Immunoassays: An Indian Population Perspective.

Authors:  Rajarshi Sarkar
Journal:  Indian J Clin Biochem       Date:  2013-05-26

3.  Interferences in immunoassay.

Authors:  Jill Tate; Greg Ward
Journal:  Clin Biochem Rev       Date:  2004-05

4.  Characteristics and clinical validity of two immunoassays for ProGRP.

Authors:  Marianne S Nordlund; Petra Stieber; Odd Terje Brustugun; David J Warren; Elisabeth Paus
Journal:  Tumour Biol       Date:  2012-03-08

5.  Prevalence of heterophilic antibodies in serum samples from horses in an equine hospital, and elimination of interference using chicken IgY.

Authors:  Bo Dong; Daniel Bergman; Bodil Ström Holst
Journal:  Acta Vet Scand       Date:  2021-03-12       Impact factor: 1.695

6.  High plasma levels of islet amyloid polypeptide in young with new-onset of type 1 diabetes mellitus.

Authors:  Johan F Paulsson; Johnny Ludvigsson; Annelie Carlsson; Rosaura Casas; Gun Forsander; Sten A Ivarsson; Ingrid Kockum; Åke Lernmark; Claude Marcus; Bengt Lindblad; Gunilla T Westermark
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

7.  Characterization of a new highly sensitive immunometric assay for thyroglobulin with reduced interference from autoantibodies.

Authors:  Marianne Nordlund Broughton; Ragnhild Nome; Ingvill Sandven; Elisabeth Paus; Trine Bjøro
Journal:  Tumour Biol       Date:  2015-12-22

8.  Characterization of canine anti-mouse antibodies highlights that multiple strategies are needed to combat immunoassay interference.

Authors:  Daniel Bergman; Anders Larsson; Helene Hansson-Hamlin; Emma Åhlén; Bodil Ström Holst
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

9.  BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.

Authors:  T Bjørge; A K Lie; E Hovig; R E Gislefoss; S Hansen; E Jellum; H Langseth; K Nustad; C G Tropé; A Dørum
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

10.  Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.

Authors:  Y Andersson; O Engebraaten; S Juell; S Aamdal; P Brunsvig; Ø Fodstad; S Dueland
Journal:  Br J Cancer       Date:  2015-11-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.